A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

被引：0
|
作者：
Nicolas Roussot
Jean-David Fumet
Emeric Limagne
Marion Thibaudin
Alice Hervieu
Audrey Hennequin
Sylvie Zanetta
Lorraine Dalens
Théo Fourrier
Loick Galland
Pierre Jacob
Aurélie Bertaut
Emilie Rederstorff
Cédric Chevalier
Sarah Ghirardi
Elodie Gilbert
Azzat Khoukaz
Etienne Martin
Constance Nicolet
Magali Quivrin
David Thibouw
Noémie Vulquin
Gilles Truc
Magali Rouffiac
Francois Ghiringhelli
Céline Mirjolet
机构：
[1] Center Georges François Leclerc,Department of Medical Oncology
[2] Center GF Leclerc,Department of Radiotherapy
[3] Cancer Biology Transfer Platform,Department of Epidemiology and Biostatistics
[4] GIMI Genetic and Immunology Medical Institute,Radiation Oncology Department, Preclinical Radiation Therapy and Radiobiology Unit
[5] University of Burgundy-Franche Comté,undefined
[6] UMR INSERM 1231,undefined
[7] Center GF Leclerc,undefined
[8] Center GF Leclerc,undefined
来源：
BMC Cancer | / 23卷
关键词：
Non-small cell lung cancer; Renal cell cancer; Bladder cancer; Head and neck cancer; PDL-1; TIGIT; Atezolizumab; Tiragolumab; Stereotactic body radiation therapy; SBRT; Immunotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer
    Roussot, Nicolas
    Fumet, Jean-David
    Limagne, Emeric
    Thibaudin, Marion
    Hervieu, Alice
    Hennequin, Audrey
    Zanetta, Sylvie
    Dalens, Lorraine
    Fourrier, Theo
    Galland, Loick
    Jacob, Pierre
    Bertaut, Aurelie
    Rederstorff, Emilie
    Chevalier, Cedric
    Ghirardi, Sarah
    Gilbert, Elodie
    Khoukaz, Azzat
    Martin, Etienne
    Nicolet, Constance
    Quivrin, Magali
    Thibouw, David
    Vulquin, Noemie
    Truc, Gilles
    Rouffiac, Magali
    Ghiringhelli, Francois
    Mirjolet, Celine
    BMC CANCER, 2023, 23 (01)
  • [2] Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors
    Yamamoto, Noboru
    Koyama, Takafumi
    Sato, Jun
    Yoshida, Tatsuya
    Sudo, Kazuki
    Iwasa, Satoru
    Kondo, Shunsuke
    Yonemori, Kan
    Kawasaki, Atsuko
    Satake, Kyoko
    Shibata, Shoyo
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (01) : 109 - 115
  • [3] A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC
    Malhotra, Jyoti
    Lin, Yong
    Patel, Malini
    Yellin, Michael J.
    Zachariah, Emmanuel
    Krier, Curtis
    Saxena, Ankit
    Jabbour, Salma K.
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (08):
  • [4] Stereotactic Body Radiation Therapy in Octogenarians With Stage I Lung Cancer
    Sandhu, Ajay P.
    Lau, Steven K. M.
    Rahn, Douglas
    Nath, Sameer K.
    Kim, Daniel
    Song, William Y.
    Gulaya, Sachin
    Fuster, Mark M.
    Bazhenova, Lyudmila
    Mundt, Arno J.
    CLINICAL LUNG CANCER, 2014, 15 (02) : 131 - 135
  • [5] Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer
    Ling, Diane C.
    Vargo, John A.
    Heron, Dwight E.
    CANCER JOURNAL, 2016, 22 (04): : 302 - 306
  • [6] AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
    Carlotta Antoniotti
    Beatrice Borelli
    Daniele Rossini
    Filippo Pietrantonio
    Federica Morano
    Lisa Salvatore
    Sara Lonardi
    Federica Marmorino
    Stefano Tamberi
    Salvatore Corallo
    Giampaolo Tortora
    Francesca Bergamo
    Di Stefano Brunella
    Alessandra Boccaccino
    Elisa Grassi
    Patrizia Racca
    Emiliano Tamburini
    Giuseppe Aprile
    Roberto Moretto
    Luca Boni
    Alfredo Falcone
    Chiara Cremolini
    BMC Cancer, 20
  • [7] AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
    Antoniotti, Carlotta
    Borelli, Beatrice
    Rossini, Daniele
    Pietrantonio, Filippo
    Morano, Federica
    Salvatore, Lisa
    Lonardi, Sara
    Marmorino, Federica
    Tamberi, Stefano
    Corallo, Salvatore
    Tortora, Giampaolo
    Bergamo, Francesca
    Brunella, Di Stefano
    Boccaccino, Alessandra
    Grassi, Elisa
    Racca, Patrizia
    Tamburini, Emiliano
    Aprile, Giuseppe
    Moretto, Roberto
    Boni, Luca
    Falcone, Alfredo
    Cremolini, Chiara
    BMC CANCER, 2020, 20 (01)
  • [8] Combination of Pembrolizumab and Stereotactic Body Radiation Therapy in Recurrent Metastatic Penile Squamous Cell Carcinoma: A Case Study
    Kaakour, Dalia
    Seyedin, Steven
    Houshyar, Roozbeh
    Mar, Nataliya
    BIOMEDICINES, 2022, 10 (12)
  • [9] Stereotactic body radiation therapy is beneficial for a subgroup of patients with urothelial cancer and solitary metastatic disease: a single institution real-world experience
    Svedman, Fernanda Costa
    Holmsten, Karin
    Jawdat, Faith
    Hailom, Wehazit
    Alm, Daniel
    Grozman, Vitali
    Ullen, Anders
    RADIATION ONCOLOGY, 2024, 19 (01)
  • [10] Advances in Stereotactic Body Radiation Therapy for Lung Cancer
    Lee, Katie N.
    Owen, Dawn
    CANCER JOURNAL, 2024, 30 (06): : 401 - 406
12345